To Be Discontinued Tablet Oncology

Nilutamide Tablet · 284 days since initial FDA posting

Brand: NILANDRON

FDA lists Nilutamide Tablet as To Be Discontinued (Advanz Pharma (US) Corp.).

No availability text on this FDA row.

Nilutamide Tablet: To Be Discontinued

FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Nilutamide Tablet
Manufacturer
Advanz Pharma (US) Corp.
Dosage Form
Tablet
Presentation
Nilandron, Tablet, 150 mg (NDC 59212-111-14)
Package NDC
59212-111-14

Status & Timeline

Status
To Be Discontinued
First Reported
Dec 1, 2025
Last Updated
Dec 1, 2025
Therapeutic Category
Oncology

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

Product to expire in March 2026; Discontinuation of the manufacture of the drug

Nearby, Other Nilutamide Shortage Records

Nilutamide Tablet

Advanz Pharma (US) Corp.

Tablet

To Be Discontinued

FDA reason on file: Product to expire in March 2026; Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.

← All Drug Shortages